|
|
| Maladies Infectieuses > Etude de marché sectorielle |
| Pipeline Insight: HIV - Extending treatment options |
|
|
|
|
€ 9 120,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Septembre 2006 |
Taille du document : |
222 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (2) |
|
|
|
| 83 pages | Septembre 2004 | Anglais
|
|
|
| Main
focus: |
antiretroviral,sexually transmitted infections,...,...
|
| Research
focus: |
market definition,market segmentation, |
| Geographic
focus: |
china,guyana,indonesia,philippines,ukraine,... |
| |
|
|
|
|
| 157 pages | Juillet 2002 | Anglais
|
|
|
| Main
focus: |
alcohol,antiretroviral,infectious disease,...
|
| Research
focus: |
demand analysis,market definition,market outlook, |
| Geographic
focus: |
usa,united kingdom |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Recommendations for Diagnostic Testing for Hepatitis C
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Tropical and Defense Vaccines - The Scared, the Weak and the Poor
99 pages | Mai 2005 |
IntroductionTropical diseases account for around 5 million deaths per year (WHO, 2002).
Major contributors to these numbers are the mosquito borne diseases, which include West Nile Fever, Japanese |
1 520,00 €
|
| |
| |
Approved AIDS and AIDS-Related Drugs, 1987-2003
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Pipeline Insight: Hepatitis B - New Kids on the Block
211 pages | Avril 2005 |
IntroductionAccording to the WHO, 350-400 million people are chronically infected with HBV progresses to liver cirrhosis and hepatocellular carcinoma.
Previously HBV has been treated with lamivudin |
9 120,00 €
|
| |
| |
The Antivirals Market Outlook: Market analysis of future growth and leading players by sector
178 pages | Janvier 2005 |
Business Insights have teamed up with IMS Health to bring you, ‘The Antivirals Market Outlook: Market analysis of future growth and leading players by sector.’ This unique product offering provides an |
2 443,75 €
|
| |
| |
Monoclonal Antibody Therapies: Evolving into a $30 billion market
360 pages | Avril 2005 |
IntroductionThe monoclonal antibody market is one of the fastest growing and most lucrative sectors of the pharmaceutical industry, with exceptional 48.1% growth between 2003 and 2004.
It has the p |
12 160,00 €
|
| |
| |
Chinese Markets for HIV Drugs
190 pages | Janvier 2003 |
China's demand for HIV drugs has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic trend |
2 835,00 €
|
| |
| |
Chinese Markets for Vaccine
269 pages | Mars 2003 |
China's demand for vaccine has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic trends, |
2 835,00 €
|
| |
| |
Stakeholder Insight: Hepatitis in China - Liver Let Die?
310 pages | Décembre 2005 |
IntroductionHepatitis is a major health problem in China, which is home to one third of hepatitis B patients and one quarter of hepatitis C patients globally.
HBV vaccination, together with HBV and |
12 920,00 €
|
| |
| |
Pipeline Insight: Hepatitis C - Small Molecules, Big Revolution
237 pages | Avril 2005 |
IntroductionLess than 50% of chronically infected hepatitis C patients do not benefit from the current standard of care, pegylated interferon plus ribavirin.
In the short-term, the treatment landsc |
9 120,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Pipeline Insight: HIV - Extending treatment options |
|
|
Introduction
More people than ever are living with HIV and AIDS in North America and Western Europe. Over the next five years, a great variety of new HIV drugs are expected to reach the market early stage therapies will be simplified by new products that will transform the market. For those with few treatment options left, new pipeline products will redefine late stage therapy.
Scope
Discussion of the epidemiology dynamics of HIV in the seven major markets, as well as the changing unmet needs that resultAssessment of late-phase clinical development compounds, competitors, and opinion leader comments on trial designForecasted sales of drugs in the antiretroviral market for the next 10 yearsExamination of the emerging drug classes including Entry Inhibitors and Integrase Inhibitors
Highlights
The increased use of antiretroviral agents has been accompanied by a rise in resistance to these drugs. Resistance generally falls into two categories: natural and acquired. The factors surrounding the development of HIV resistance are interrelated and include poor drug compliance, pharmacological factors, and direct molecular drug resistance.
Atripla, approved in the US in July 2006, has been one of the greatest developments in HIV therapy. A combination of two class leaders, Truvada and Sustiva, the triple pill is the first to combine the components of HAART into a single pill formulation taken once daily. Datamonitor forecasts it to reach peak sales in excess of $2 billion.
Integrase inhibitors MK-0518 and GS-9137 look to be the most promising candidates in the EI and others pipeline. Of the two, MK-0518 is the most advanced and looks set to dominate the salvage market.
Reasons to Purchase
Understand key drivers in the antiretroviral market and predict the future performance of key compoundsExplore the changing unmet needs of patients and clinical endpoints used in current trial designEvaluate forecasts for the antiretroviral market to 2015, taking into account key launch dates, patent expiries and generic incursion
|
|
Introduction
More people than ever are living with HIV and AIDS in North America and Western Europe. Over the next five years, a great variety of new HIV drugs are expected to reach the market early stage therapies will be simplified by new products that will transform the market. For those with few treatment options left, new pipeline products will redefine late stage therapy.
Scope
Discussion of the epidemiology dynamics of HIV in the seven major markets, as well as the changing unmet needs that resultAssessment of late-phase clinical development compounds, competitors, and opinion leader comments on trial designForecasted sales of drugs in the antiretroviral market for the next 10 yearsExamination of the emerging drug classes including Entry Inhibitors and Integrase Inhibitors
Highlights
The increased use of antiretroviral agents has been accompanied by a rise in resistance to these drugs. Resistance generally falls into two categories: natural and acquired. The factors surrounding the development of HIV resistance are interrelated and include poor drug compliance, pharmacological factors, and direct molecular drug resistance.
Atripla, approved in the US in July 2006, has been one of the greatest developments in HIV therapy. A combination of two class leaders, Truvada and Sustiva, the triple pill is the first to combine the components of HAART into a single pill formulation taken once daily. Datamonitor forecasts it to reach peak sales in excess of $2 billion.
Integrase inhibitors MK-0518 and GS-9137 look to be the most promising candidates in the EI and others pipeline. Of the two, MK-0518 is the most advanced and looks set to dominate the salvage market.
Reasons to Purchase
Understand key drivers in the antiretroviral market and predict the future performance of key compoundsExplore the changing unmet needs of patients and clinical endpoints used in current trial designEvaluate forecasts for the antiretroviral market to 2015, taking into account key launch dates, patent expiries and generic incursion
|
|
|
PPLSEN
|
|
|
|
|
